Brief: Rain Therapeutics Inc Q2 basic EPS USD -0.61
10/08/2023 22:06
Aug 10 (Reuters) - Rain Therapeutics Inc Q2 basic EPS USD -0.61. * Q2 net income USD -22.064 million * Q2 income from operations USD -23.231 million * Q2 operating expenses USD 23.231 million
Recent news on Rain Oncology
See all newsBrief: Rain Enhancement Technologies Holdco - May Offer Up To $25 Million In Securities From Time To Time - SEC Filing
Brief: Rain Enhancement Technologies Holdco Inc - Q1 And Q2 2025 Financial Statements Should Not Be Relied Upon Due To Accounting Error - SEC Filing
Brief: Rain Oncology Pursuant To Proposed Deal With Pathos AI
Brief: Rain Oncology To Be Acquired By Pathos AI For $1.16 In Cash Per Share Plus Contingent Value Rights
Brief: Rain Oncology Q3 Net Income USD -7.034 Million